NCT00570882
Completed
Phase 2
A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma
ConditionsMetastatic Renal Cell Carcinoma
Overview
- Phase
- Phase 2
- Intervention
- Sunitinib 4/2
- Conditions
- Metastatic Renal Cell Carcinoma
- Sponsor
- Asan Medical Center
- Enrollment
- 76
- Locations
- 3
- Primary Endpoint
- Treatment failure rate (progressive disease, treatment withdrawal due to unacceptable toxicities, or any death)
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
This study is to evaluate the efficacy, safety, and feasibility of sunitinib in 4/2 and 2/1 regimen in previously untreated metastatic RCC to select the most promising regimen, which should be used in further studies of this patient population.
Investigators
JLee
Associate professor
Asan Medical Center
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically confirmation of renal cell carcinoma with a clear cell histologic component
- •Patients must present with stage IV disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent.
- •Measurable disease according to RECIST criteria are required but patients with evaluable lesions without measurable lesions are allowed to be enrolled to this study
- •ECOG performance status 2 or better
- •Age 18 years or older
- •Adequate bone marrow, hepatic, and renal function
- •Life expectancy of \> 3 months
- •Singed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
Exclusion Criteria
- •Known spinal cord compression or carcinomatous meningitis
- •Diagnosis of any serious secondary malignancy within the last 2 years, except for adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma of cervix uteri
- •Hypertension that cannot be controlled by medications (blood pressure \> 150/90 mmHg despite optimal medical therapy)
- •Treatment with anticonvulsant agents and treatment with therapeutic doses of coumadin currently or within 2 weeks prior to first day of sunitinib administration. Low dose coumadin for DVT prophylaxis is permitted (up to 2 mg/day).
- •Pregnancy or breast feeding.
- •Other severe acute or chronic medical or psychiatric condition
- •Prior treatment on sunitinib, sorafenib, or bevacizumab.
Arms & Interventions
Sunitinib 4/2
Sunitinib 50 mg PO 4-week on and 2-week off
Intervention: Sunitinib 4/2
Sunitinib 2/1
Sunitinib 50 mg PO 2-week on 1-week off
Intervention: Sunitinib 2/1
Outcomes
Primary Outcomes
Treatment failure rate (progressive disease, treatment withdrawal due to unacceptable toxicities, or any death)
Time Frame: 12 months
From the date of randomization to the date of progressive disease, treatment withdrawal, or death from any cause, which came first.
Secondary Outcomes
- quality of life(12 months)
- Progression free survival(12 months)
- Adverse events(about 12 months)
- Overall survival(36 months)
- Overall response rate(6 months)
Study Sites (3)
Loading locations...
Similar Trials
Completed
Phase 2
Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By SurgeryCervical AdenocarcinomaCervical Adenosquamous Cell CarcinomaCervical Squamous Cell CarcinomaRecurrent Cervical CancerStage IVB Cervical CancerNCT00389974National Cancer Institute (NCI)19
Completed
Phase 2
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerRecurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian Epithelial CancerStage IIIA Primary Peritoneal Cavity CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian Epithelial CancerStage IIIB Primary Peritoneal Cavity CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian Epithelial CancerStage IIIC Primary Peritoneal Cavity CancerStage IV Fallopian Tube CancerStage IV Ovarian Epithelial CancerStage IV Primary Peritoneal Cavity CancerNCT00388037National Cancer Institute (NCI)31
Completed
Phase 2
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)Genitourinary CancerKidney CancerNCT02060370M.D. Anderson Cancer Center60
Completed
Phase 2
Efficacy and Safety of Sunitinib in Metastatic Gastric CancerGastric AdenocarcinomaBarrett EsophagusNCT00411151Johannes Gutenberg University Mainz52
Completed
Phase 2
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung CancerLung CancerNCT00620347National Cancer Center, Korea25